Copyright Reports & Markets. All rights reserved.

Global Ulcerative Colitis Immunology Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Ulcerative Colitis Immunology Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by Product
      • 1.4.2 Adalimumab
      • 1.4.3 Certolizumab Pegol
      • 1.4.4 Tofacitinib
      • 1.4.5 Etanercept
      • 1.4.6 Golimumab
      • 1.4.7 Abatacept
      • 1.4.8 Infliximab
      • 1.4.9 Others
    • 1.5 Market by End User
      • 1.5.1 Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by End User
      • 1.5.2 Rheumatoid Arthritis
      • 1.5.3 Crohn's Disease(CD)
      • 1.5.4 Ankylosing Spondylitis(AS)
      • 1.5.5 Psoriasis(Ps)
      • 1.5.6 Ulcerative Colitis(UC)
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Ulcerative Colitis Immunology Drugs Market Size
      • 2.1.1 Global Ulcerative Colitis Immunology Drugs Revenue 2014-2025
      • 2.1.2 Global Ulcerative Colitis Immunology Drugs Sales 2014-2025
    • 2.2 Ulcerative Colitis Immunology Drugs Growth Rate by Regions
      • 2.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Regions
      • 2.2.2 Global Ulcerative Colitis Immunology Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Ulcerative Colitis Immunology Drugs Sales by Manufacturers
      • 3.1.1 Ulcerative Colitis Immunology Drugs Sales by Manufacturers
      • 3.1.2 Ulcerative Colitis Immunology Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Ulcerative Colitis Immunology Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Ulcerative Colitis Immunology Drugs Revenue by Manufacturers
      • 3.2.1 Ulcerative Colitis Immunology Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Ulcerative Colitis Immunology Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Ulcerative Colitis Immunology Drugs Price by Manufacturers
    • 3.4 Ulcerative Colitis Immunology Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Ulcerative Colitis Immunology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Ulcerative Colitis Immunology Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Ulcerative Colitis Immunology Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Ulcerative Colitis Immunology Drugs Sales by Product
    • 4.2 Global Ulcerative Colitis Immunology Drugs Revenue by Product
    • 4.3 Ulcerative Colitis Immunology Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Ulcerative Colitis Immunology Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Ulcerative Colitis Immunology Drugs by Countries
      • 6.1.1 North America Ulcerative Colitis Immunology Drugs Sales by Countries
      • 6.1.2 North America Ulcerative Colitis Immunology Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Ulcerative Colitis Immunology Drugs by Product
    • 6.3 North America Ulcerative Colitis Immunology Drugs by End User

    7 Europe

    • 7.1 Europe Ulcerative Colitis Immunology Drugs by Countries
      • 7.1.1 Europe Ulcerative Colitis Immunology Drugs Sales by Countries
      • 7.1.2 Europe Ulcerative Colitis Immunology Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Ulcerative Colitis Immunology Drugs by Product
    • 7.3 Europe Ulcerative Colitis Immunology Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Ulcerative Colitis Immunology Drugs by Countries
      • 8.1.1 Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Countries
      • 8.1.2 Asia Pacific Ulcerative Colitis Immunology Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Ulcerative Colitis Immunology Drugs by Product
    • 8.3 Asia Pacific Ulcerative Colitis Immunology Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Ulcerative Colitis Immunology Drugs by Countries
      • 9.1.1 Central & South America Ulcerative Colitis Immunology Drugs Sales by Countries
      • 9.1.2 Central & South America Ulcerative Colitis Immunology Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Ulcerative Colitis Immunology Drugs by Product
    • 9.3 Central & South America Ulcerative Colitis Immunology Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Ulcerative Colitis Immunology Drugs by Countries
      • 10.1.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Ulcerative Colitis Immunology Drugs by Product
    • 10.3 Middle East and Africa Ulcerative Colitis Immunology Drugs by End User

    11 Company Profiles

    • 11.1 Janssen Biotech, Inc.
      • 11.1.1 Janssen Biotech, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Products Offered
      • 11.1.5 Janssen Biotech, Inc. Recent Development
    • 11.2 Bristol-Myers Squibb Company
      • 11.2.1 Bristol-Myers Squibb Company Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Products Offered
      • 11.2.5 Bristol-Myers Squibb Company Recent Development
    • 11.3 AbbVie Inc.
      • 11.3.1 AbbVie Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Products Offered
      • 11.3.5 AbbVie Inc. Recent Development
    • 11.4 UCBCares
      • 11.4.1 UCBCares Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 UCBCares Ulcerative Colitis Immunology Drugs Products Offered
      • 11.4.5 UCBCares Recent Development
    • 11.5 AMGEN
      • 11.5.1 AMGEN Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 AMGEN Ulcerative Colitis Immunology Drugs Products Offered
      • 11.5.5 AMGEN Recent Development
    • 11.6 Celltrion Healthcare
      • 11.6.1 Celltrion Healthcare Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Products Offered
      • 11.6.5 Celltrion Healthcare Recent Development
    • 11.7 Biogen
      • 11.7.1 Biogen Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Biogen Ulcerative Colitis Immunology Drugs Products Offered
      • 11.7.5 Biogen Recent Development
    • 11.8 Genentech USA, Inc.
      • 11.8.1 Genentech USA, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Products Offered
      • 11.8.5 Genentech USA, Inc. Recent Development
    • 11.9 ROCHE
      • 11.9.1 ROCHE Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 ROCHE Ulcerative Colitis Immunology Drugs Products Offered
      • 11.9.5 ROCHE Recent Development
    • 11.10 Pfizer Inc.
      • 11.10.1 Pfizer Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Products Offered
      • 11.10.5 Pfizer Inc. Recent Development

    12 Future Forecast

    • 12.1 Ulcerative Colitis Immunology Drugs Market Forecast by Regions
      • 12.1.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Ulcerative Colitis Immunology Drugs Market Forecast by Product
      • 12.2.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Ulcerative Colitis Immunology Drugs Market Forecast by End User
    • 12.4 North America Ulcerative Colitis Immunology Drugs Forecast
    • 12.5 Europe Ulcerative Colitis Immunology Drugs Forecast
    • 12.6 Asia Pacific Ulcerative Colitis Immunology Drugs Forecast
    • 12.7 Central & South America Ulcerative Colitis Immunology Drugs Forecast
    • 12.8 Middle East and Africa Ulcerative Colitis Immunology Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Ulcerative Colitis Immunology Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Ulcerative Colitis Immunology Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Ulcerative Colitis Immunology Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Ulcerative Colitis Immunology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Ulcerative Colitis Immunology Drugs in these regions.
      This research report categorizes the global Ulcerative Colitis Immunology Drugs market by top players/brands, region, type and end user. This report also studies the global Ulcerative Colitis Immunology Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Janssen Biotech, Inc.
      Bristol-Myers Squibb Company
      AbbVie Inc.
      UCBCares
      AMGEN
      Celltrion Healthcare
      Biogen
      Genentech USA, Inc.
      ROCHE
      Pfizer Inc.

      Market size by Product
      Adalimumab
      Certolizumab Pegol
      Tofacitinib
      Etanercept
      Golimumab
      Abatacept
      Infliximab
      Others
      Market size by End User
      Rheumatoid Arthritis
      Crohn's Disease(CD)
      Ankylosing Spondylitis(AS)
      Psoriasis(Ps)
      Ulcerative Colitis(UC)

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Ulcerative Colitis Immunology Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Ulcerative Colitis Immunology Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Ulcerative Colitis Immunology Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Ulcerative Colitis Immunology Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Ulcerative Colitis Immunology Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Ulcerative Colitis Immunology Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now